As global markets rebound from recent sell-offs, with growth stocks notably outpacing value shares, the technology sector has ...

The "Cell Therapy Manufacturing Market (6th Edition): Industry Trends and Global Forecasts to 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and ...

IBBQ is a relatively new US biotech ETF that competes with established peers like IBB and XBI. Read why I don't recommend ...

Comparing Gilead Sciences, Inc. and AbbVie Inc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your ...

Comparing Gilead Sciences, Inc. and Bristol-Myers Squibb Co’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at ...

Here are some of the other top SWAN ETFs to consider. The Invesco S&P 500 Revenue ETF is one of the top SWAN ETFs to have in ...

Financial writer rates Mereo BioPharma stock as Hold despite recent positive data, citing uncertainties around Phase 3 ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

Gilead Sciences (GILD) closed at $83.08 in the latest trading session, marking a -0.1% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.03%. Meanwhile ...